tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Purple Biotech Receives Nasdaq Bid Price Notification

Story Highlights
  • Purple Biotech is a clinical-stage company developing therapies for tumor immune evasion.
  • The company received a Nasdaq notification for non-compliance with the minimum bid price rule.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Purple Biotech Receives Nasdaq Bid Price Notification

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Purple Biotech ( (PPBT) ) just unveiled an update.

On October 16, 2025, Purple Biotech received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its American Depositary Shares (ADSs) have been below $1.00 for 30 consecutive trading days. The company has until April 14, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for ten consecutive business days. This notification does not immediately affect the company’s Nasdaq listing or the trading of its ADSs, and the company is considering options to address the deficiency, including adjusting the ratio between its ADSs and ordinary shares.

The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Spark’s Take on PPBT Stock

According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.

Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.

To see Spark’s full report on PPBT stock, click here.

More about Purple Biotech

Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to address tumor immune evasion and drug resistance. Its oncology pipeline includes CAPTN-3, CM24, and NT219, which are designed to engage immune cells and target tumor-associated antigens to enhance anti-tumoral responses. The company is headquartered in Rehovot, Israel, and its shares are traded on NASDAQ and the Tel Aviv Stock Exchange.

Average Trading Volume: 1,084,089

Technical Sentiment Signal: Sell

Current Market Cap: $6.01M

See more insights into PPBT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1